Jose Manuel De Jesus Martinez Manzano, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Angioedema | 3 | 2021 | 184 | 2.010 |
Why?
|
Pulmonary Infarction | 1 | 2023 | 11 | 0.900 |
Why?
|
Dihydropyridines | 1 | 2021 | 67 | 0.780 |
Why?
|
Lisinopril | 1 | 2021 | 60 | 0.730 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 1504 | 0.710 |
Why?
|
Tranexamic Acid | 1 | 2021 | 172 | 0.610 |
Why?
|
Antifibrinolytic Agents | 1 | 2021 | 287 | 0.580 |
Why?
|
Hypertension, Pulmonary | 2 | 2024 | 1592 | 0.540 |
Why?
|
Pulmonary Embolism | 3 | 2023 | 2571 | 0.510 |
Why?
|
Respiratory Insufficiency | 1 | 2023 | 1232 | 0.480 |
Why?
|
Hemodynamics | 1 | 2024 | 4165 | 0.450 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2254 | 0.430 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1331 | 0.430 |
Why?
|
Calcium Channel Blockers | 2 | 2021 | 691 | 0.300 |
Why?
|
Patient Readmission | 1 | 2021 | 3265 | 0.280 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3201 | 0.270 |
Why?
|
Idiopathic Pulmonary Fibrosis | 2 | 2020 | 514 | 0.230 |
Why?
|
Asthma | 1 | 2021 | 6230 | 0.200 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2024 | 290 | 0.180 |
Why?
|
Arteriovenous Fistula | 1 | 2024 | 319 | 0.180 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 392 | 0.150 |
Why?
|
Pulmonary Fibrosis | 1 | 2021 | 505 | 0.140 |
Why?
|
Acute Disease | 2 | 2023 | 7226 | 0.130 |
Why?
|
Cardiovascular System | 1 | 2023 | 836 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2020 | 1168 | 0.130 |
Why?
|
Ubiquitin | 1 | 2020 | 839 | 0.120 |
Why?
|
Retrospective Studies | 8 | 2024 | 80674 | 0.120 |
Why?
|
Renal Dialysis | 1 | 2024 | 1796 | 0.120 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1318 | 0.110 |
Why?
|
Respiration, Artificial | 1 | 2023 | 2631 | 0.100 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 918 | 0.090 |
Why?
|
Family | 1 | 2020 | 3192 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2944 | 0.080 |
Why?
|
Calcium | 1 | 2021 | 5719 | 0.080 |
Why?
|
Genetic Testing | 1 | 2021 | 3537 | 0.070 |
Why?
|
Aged | 6 | 2024 | 169288 | 0.060 |
Why?
|
Humans | 12 | 2024 | 761208 | 0.060 |
Why?
|
Middle Aged | 7 | 2024 | 220853 | 0.060 |
Why?
|
Mass Screening | 1 | 2021 | 5426 | 0.060 |
Why?
|
Lung | 2 | 2020 | 9979 | 0.060 |
Why?
|
Female | 7 | 2024 | 392544 | 0.040 |
Why?
|
Male | 6 | 2024 | 360693 | 0.040 |
Why?
|
Troponin | 1 | 2023 | 504 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74239 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1897 | 0.040 |
Why?
|
Protein Folding | 1 | 2020 | 869 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2020 | 1685 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2023 | 2055 | 0.030 |
Why?
|
Pedigree | 1 | 2021 | 4537 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2020 | 1720 | 0.030 |
Why?
|
Cohort Studies | 2 | 2024 | 41496 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4431 | 0.020 |
Why?
|
Homeostasis | 1 | 2020 | 3320 | 0.020 |
Why?
|
Anticoagulants | 1 | 2023 | 4795 | 0.020 |
Why?
|
Disease Progression | 1 | 2020 | 13511 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15721 | 0.010 |
Why?
|
Prognosis | 1 | 2023 | 29687 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26071 | 0.010 |
Why?
|
Risk Assessment | 1 | 2023 | 24021 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39126 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 39957 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 15520 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2023 | 58952 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20588 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2023 | 64681 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81326 | 0.010 |
Why?
|
Adult | 1 | 2023 | 221119 | 0.000 |
Why?
|
Animals | 1 | 2020 | 168079 | 0.000 |
Why?
|